April 18, 2018
Announcement no. 9

Ole Larsen, Executive Vice President & CFO of Bavarian Nordic, will as of June 1, 2018, join BioPorto as the new Chief Financial Officer. 

In 2008, Ole Larsen joined Bavarian Nordic as Executive Vice President & CFO. Bavarian Nordic is listed on NASDAQ Copenhagen.
It has 400+ employees and an annual turnover in 2017 of DKK 1.37 billion. During his 10 year tenure the market cap of Bavarian Nordic increased from DKK 1 billion to almost DKK 6 billion.

Peter M. Eriksen says: “We are very excited to welcome Ole to our management team. With his comprehensive experience and knowledge in the industry, I know that Ole will be a valuable contributor to the future of BioPorto.”

Ole Larsen says: “BioPorto is a highly exciting company with a very interesting product portfolio, an ambitious strategy and a huge potential that I am proud to join. I look forward to join and work with the entire team to create value for patients, customers and shareholders.”

The Executive Management of BioPorto is led by Peter M. Eriksen, while the Board of Directors is composed of Thomas Magnussen (Chairman), Torben A. Nielsen (Vice Chairman), Kirsten Drejer and Britt Meelby.

For further information, please contact:
Peter M. Eriksen, CEO
Gry Husby Larsen, Investor Relations
Telephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGAL
Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million dies. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.

About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock exchange.

Attachment